Vertex Pharmaceuticals
Get verified emails for Vertex Pharmaceuticals employeesAbout Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It develops medicines for people with serious diseases, with work spanning discovery, research, development, and commercialization through R&D sites and commercial offices worldwide.
Cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain are the company’s main areas of work. Here, Vertex has made clinical progress and continues to advance research programs, while also maintaining a clinical pipeline of investigational therapies in acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1.
Vertex employs between 5,001 and 10,000 people and serves patients with serious diseases across a global footprint. Its research and medicines have received external recognition, and the company has been named by Science Magazine, The Boston Globe, Boston Business Journal, and the San Diego Business Journal as a notable place to work.
Need to reach the Vertex Pharmaceuticals team directly? Find verified work emails for every employee with Snov.io
Insights
Updated 31 Aug 2026Vertex Pharmaceuticals is being grouped by MarketBeat’s stock screener with other closely watched biotech names such as Moderna, AbbVie, Amgen, Danaher, Gilead Sciences, and Alnylam Pharmaceuticals. That points to it staying inside the core large-cap biotech peer set that investors are tracking. No product updates or trial data appear in the available sources, so the main signal is comparative: Vertex is being viewed beside major, diversified biotech rivals rather than as a niche outlier.
Strategically, the sources give no operational detail on Vertex’s pipeline or any shift in the business. Still, its repeated appearance in "biotech stocks to watch" lists shows that the company continues to draw market attention within the broader life sciences sector, where it is screened alongside firms focused on medicines, vaccines, genetic therapies, and diagnostic technologies. That is a familiar framing. It keeps Vertex in the mix.
Investor sentiment looks mixed, but active. UBS AM increased its holdings in Vertex by 1.0% in the second quarter, while Van ECK Associates Corp reduced its stake by 1.5%; Caisse de depot et placement du Quebec also opened a new position in the stock during the same period. Those filings indicate that institutional interest remains in place, even as some managers trim exposure.
Frequently asked questions
Vertex Pharmaceuticals is headquartered in Boston, Massachusetts, United States.
Vertex Pharmaceuticals has 5001-10000 employees according to its company profile.
Vertex Pharmaceuticals operates in the Biotechnology sector. Public valuation figures are not always disclosed for private companies.